Brokerages Set Monopar Therapeutics Inc. (NASDAQ:MNPR) PT at $60.00

Monopar Therapeutics Inc. (NASDAQ:MNPR - Get Free Report) has been assigned a consensus rating of "Moderate Buy" from the six analysts that are covering the firm, Marketbeat Ratings reports. One research analyst has rated the stock with a hold recommendation and five have issued a buy recommendation on the company. The average 1-year price target among analysts that have updated their coverage on the stock in the last year is $60.00.

Several equities analysts have weighed in on MNPR shares. Cantor Fitzgerald began coverage on shares of Monopar Therapeutics in a report on Monday, July 7th. They issued an "overweight" rating and a $74.00 target price on the stock. Chardan Capital assumed coverage on shares of Monopar Therapeutics in a report on Monday, June 23rd. They issued a "buy" rating and a $60.00 price target on the stock. Wall Street Zen upgraded shares of Monopar Therapeutics from a "sell" rating to a "hold" rating in a report on Thursday, May 22nd. Jones Trading restated a "hold" rating on shares of Monopar Therapeutics in a research note on Wednesday, April 2nd. Finally, HC Wainwright reaffirmed a "buy" rating and issued a $40.00 price target on shares of Monopar Therapeutics in a report on Tuesday, April 1st.

Insider Activity at Monopar Therapeutics

In other news, Director Christopher M. Starr sold 16,800 shares of the business's stock in a transaction that occurred on Monday, July 14th. The shares were sold at an average price of $40.00, for a total transaction of $672,000.00. Following the sale, the director owned 5,173 shares in the company, valued at $206,920. The trade was a 76.46% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director Kim R. Tsuchimoto sold 8,904 shares of the stock in a transaction dated Monday, July 14th. The stock was sold at an average price of $40.00, for a total transaction of $356,160.00. Following the sale, the director owned 11,486 shares of the company's stock, valued at $459,440. This trade represents a 43.67% decrease in their position. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 42,504 shares of company stock worth $1,700,160. 20.50% of the stock is currently owned by corporate insiders.

Institutional Trading of Monopar Therapeutics

A number of large investors have recently made changes to their positions in the stock. AlphaQuest LLC purchased a new stake in Monopar Therapeutics during the 1st quarter worth about $44,000. JPMorgan Chase & Co. purchased a new position in Monopar Therapeutics in the fourth quarter valued at about $45,000. Gerber LLC acquired a new position in Monopar Therapeutics in the first quarter worth about $204,000. OMERS ADMINISTRATION Corp bought a new position in Monopar Therapeutics in the first quarter worth about $328,000. Finally, Jane Street Group LLC bought a new stake in shares of Monopar Therapeutics during the first quarter valued at approximately $377,000. 1.83% of the stock is owned by hedge funds and other institutional investors.

Monopar Therapeutics Price Performance

NASDAQ MNPR traded down $0.05 on Friday, reaching $46.43. The company had a trading volume of 29,618 shares, compared to its average volume of 362,661. Monopar Therapeutics has a 1 year low of $1.72 and a 1 year high of $54.30. The firm has a 50-day moving average of $35.86 and a 200-day moving average of $36.41. The firm has a market capitalization of $284.15 million, a PE ratio of -13.34 and a beta of 1.01.

Monopar Therapeutics (NASDAQ:MNPR - Get Free Report) last released its quarterly earnings data on Tuesday, May 13th. The company reported ($0.38) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.65) by $0.27. As a group, sell-side analysts expect that Monopar Therapeutics will post -1.65 EPS for the current fiscal year.

About Monopar Therapeutics

Monopar Therapeutics Inc, a clinical-stage biopharmaceutical company, engages in developing therapeutics for the treatment of cancer in the United States. Its lead product candidate in development is Validive, a clonidine hydrochloride mucobuccal tablet that is in Phase 2b/3 clinical trial for the prevention of chemoradiotherapy induced severe oral mucositis in patients with oropharyngeal cancer.